BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Park JK, Lee SH, Kang JH, Nishio K, Saijo N, Kuh HJ. Synergistic interaction between gefitinib (Iressa, ZD1839) and paclitaxel against human gastric carcinoma cells. Anticancer Drugs. 2004;15:809-818. [PMID: 15494644 DOI: 10.1097/00001813-200409000-00011] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.2] [Reference Citation Analysis]
Number Citing Articles
1 Chen S, Jiang X, Liu R, Huang Y, Shen W, Jiang Y, Huang K, Liu Y. New cytotoxic zinc(II) and copper(II) complexes of Schiff base ligands derived from homopiperonylamine and halogenated salicylaldehyde. Inorganica Chimica Acta 2021;516:120171. [DOI: 10.1016/j.ica.2020.120171] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
2 Shi XQ, Xue WH, Zhao SF, Zhang XJ, Sun W. Dynamic tracing for epidermal growth factor receptor mutations in urinary circulating DNA in gastric cancer patients. Tumour Biol 2017;39:1010428317691681. [PMID: 28222666 DOI: 10.1177/1010428317691681] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
3 Kim SA, Kim I, Yoon SK, Lee EK, Kuh HJ. Indirect modulation of sensitivity to 5-fluorouracil by microRNA-96 in human colorectal cancer cells. Arch Pharm Res. 2015;38:239-248. [PMID: 25502560 DOI: 10.1007/s12272-014-0528-9] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 3.6] [Reference Citation Analysis]
4 Ochoa G, Villasana M. Population-based optimization of cytostatic/cytotoxic combination cancer chemotherapy. Soft Comput 2013;17:913-24. [DOI: 10.1007/s00500-013-1043-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
5 Yoong J, Michael M, Leong T. Targeted therapies for gastric cancer: current status. Drugs. 2011;71:1367-1384. [PMID: 21812503 DOI: 10.2165/11592530-000000000-00000] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 3.0] [Reference Citation Analysis]
6 Tu JH, Yu YH. Role of epidermal growth factor receptor inhibitors in the treatment of gastric carcinoma. Shijie Huaren Xiaohua Zazhi 2011; 19(11): 1150-1155 [DOI: 10.11569/wcjd.v19.i11.1150] [Reference Citation Analysis]
7 Villasana M, Ochoa G, Aguilar S. Modeling and optimization of combined cytostatic and cytotoxic cancer chemotherapy. Artif Intell Med 2010;50:163-73. [PMID: 20620035 DOI: 10.1016/j.artmed.2010.05.009] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
8 Lyros O, Mueller A, Heidel F, Schimanski CC, Gockel I, Galle PR, Lang H, Moehler M. Analysis of anti-proliferative and chemosensitizing effects of sunitinib on human esophagogastric cancer cells: Synergistic interaction with vandetanib via inhibition of multi-receptor tyrosine kinase pathways. Int J Cancer 2010;127:1197-208. [PMID: 20039326 DOI: 10.1002/ijc.25137] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 1.5] [Reference Citation Analysis]
9 Ko JC, Wang LH, Jhan JY, Ciou SC, Hong JH, Lin ST, Lin YW. The role of celecoxib in Rad51 expression and cell survival affected by gefitinib in human non-small cell lung cancer cells. Lung Cancer 2009;65:290-8. [PMID: 19157634 DOI: 10.1016/j.lungcan.2008.12.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
10 Chang GC, Yu CT, Tsai CH, Tsai JR, Chen JC, Wu CC, Wu WJ, Hsu SL. An epidermal growth factor inhibitor, Gefitinib, induces apoptosis through a p53-dependent upregulation of pro-apoptotic molecules and downregulation of anti-apoptotic molecules in human lung adenocarcinoma A549 cells. Eur J Pharmacol 2008;600:37-44. [PMID: 18973751 DOI: 10.1016/j.ejphar.2008.10.024] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
11 Wadler S. Molecular Targeting in Upper Gastrointestinal Malignancies. Cancer Drug Discovery and Development. [DOI: 10.1007/978-1-59745-337-0_6] [Reference Citation Analysis]
12 Suttie SA, Park KG, Smith TA. [18F]2-fluoro-2-deoxy-D-glucose incorporation by AGS gastric adenocarcinoma cells in vitro during response to epirubicin, cisplatin and 5-fluorouracil. Br J Cancer 2007;97:902-9. [PMID: 17848947 DOI: 10.1038/sj.bjc.6603971] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 0.5] [Reference Citation Analysis]
13 Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58:621-681. [PMID: 16968952 DOI: 10.1124/pr.58.3.10] [Cited by in Crossref: 3327] [Cited by in F6Publishing: 3485] [Article Influence: 195.7] [Reference Citation Analysis]
14 Green J, Ikram M, Vyas J, Patel N, Proby CM, Ghali L, Leigh IM, O'Toole EA, Storey A. Overexpression of the Axl tyrosine kinase receptor in cutaneous SCC-derived cell lines and tumours. Br J Cancer 2006;94:1446-51. [PMID: 16641895 DOI: 10.1038/sj.bjc.6603135] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 2.2] [Reference Citation Analysis]
15 Shimoyama T, Koizumi F, Fukumoto H, Kiura K, Tanimoto M, Saijo N, Nishio K. Effects of different combinations of gefitinib and irinotecan in lung cancer cell lines expressing wild or deletional EGFR. Lung Cancer 2006;53:13-21. [DOI: 10.1016/j.lungcan.2006.03.014] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
16 Becker J, Müller-Tidow C, Serve H, Domschke W, Pohle T. Role of receptor tyrosine kinases in gastric cancer: New targets for a selective therapy. World J Gastroenterol 2006; 12(21): 3297-3305 [PMID: 16733844 DOI: 10.3748/wjg.v12.i21.3297] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 44] [Article Influence: 2.3] [Reference Citation Analysis]
17 Okano J, Matsumoto K, Nagahara T, Murawaki Y. Gefitinib and the modulation of the signaling pathways downstream of epidermal growth factor receptor in human liver cancer cells. J Gastroenterol 2006;41:166-76. [PMID: 16568376 DOI: 10.1007/s00535-005-1736-3] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 1.3] [Reference Citation Analysis]
18 Jantová S, Letašiová S, Repický A, Ovádeková R, Lakatoš B. The effect of 3-(5-nitro-2-thienyl)-9-chloro-5-morpholin-4-yl[1,2,4]triazolo[4,3-c]quinazoline on cell growth, cell cycle, induction of DNA fragmentation, and activity of caspase 3 in murine leukemia L1210 cells and fibroblast NIH-3T3 cells. Cell Biochem Funct 2006;24:519-30. [DOI: 10.1002/cbf.1296] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
19 Varadhachary GR, Yu C, Ajani JA. Status of Newer Chemotherapeutic Strategies for the Treatment of Metastatic Gastric Cancer. American Journal of Cancer 2005;4:65-70. [DOI: 10.2165/00024669-200504010-00005] [Reference Citation Analysis]